

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4571708
<b>Application Number:</b>	10574101
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7472
<b>Title of Invention:</b>	Pyrimidin-2-Amine Derivatives and Their Use as A2b Adenosine Receptor Antagonists
<b>First Named Inventor/Applicant Name:</b>	Bernat Vidal Juan
<b>Customer Number:</b>	22852
<b>Filer:</b>	Carlos M. Tellez
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	09605.0017
<b>Receipt Date:</b>	07-JAN-2009
<b>Filing Date:</b>	08-MAR-2007
<b>Time Stamp:</b>	16:51:12
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$310
RAM confirmation Number	2157
Deposit Account	
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part/.zip	Pages (if appl.)

1		09605-0017--07-JAN-09-- ResponseandEoT--FINAL.pdf	1089455 a2df0cdf97542e7fa1b770b4350fbfc606c78 fe1	yes	21
<b>Multipart Description/PDF files in .zip description</b>					
<b>Document Description</b>		<b>Start</b>		<b>End</b>	
Amendment/Req. Reconsideration-After Non-Final Reject		1		1	
Claims		2		11	
Applicant Arguments/Remarks Made in an Amendment		12		21	

**Warnings:****Information:**

2		09605-0017--07--JAN-09-- SecondSupplmenetalIDS.pdf	228744 2bb7afcb07a7525ff6a13068a9560ef67a95 0f98	yes	3
<b>Multipart Description/PDF files in .zip description</b>					
<b>Document Description</b>		<b>Start</b>		<b>End</b>	
Information Disclosure Statement Letter		1		2	
Information Disclosure Statement (IDS) Filed (SB/08)		3		3	

**Warnings:****Information:**

3	NPL Documents	09605-0017-07-JAN-09-- HolgateUnivSouthampton2005 roleA2Binasthma-Reference- IDS.pdf	169902 4c3d48ecc717b9e2e1a15d6c716562436b 64275	no	7
---	---------------	---	---	----	---

**Warnings:****Information:**

4	NPL Documents	09605-0017--07-JAN-09-- ExpertOpinThePatents-2006-1 6-10-Reference-IDS.pdf	185709 6218f7b6d7c7818d29e2f791ce16fb9b528f c507	no	11
---	---------------	--	--	----	----

**Warnings:****Information:**

5	NPL Documents	09605-0017--07-JAN-09-- Hasko2008NatureRevDrugDisc covery--Reference-IDS.pdf	568606 f7a92dcae27aaeb4fed6ca4f173b6ca6bd28 cc82	no	12
---	---------------	--	--	----	----

**Warnings:****Information:**

6	NPL Documents	09605-0017--07-JAN-09-- HaskoandCronsteinTrendsInIm munology-2004--Reference- IDS.pdf	415009 8e52af9ddc892d71e156365d47ddb0854e0 afd96	no	7
---	---------------	--	--	----	---

**Warnings:**

<b>Information:</b>					
7	NPL Documents	09605-0017--07-JAN-09-- JacobsonGaoNIHBethesda2006 NatureReviewsDrugDiscovery5 --Reference-IDS.pdf	1005640 1d4897826be973c1ed866982327663d689 7a209f	no	18
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	09605-0017--07-JAN-09-- MINIREVMEDCACCARI2005-- Reference-IDS.pdf	1207090 073f6ceee52eec3573e9a626570062943e6a 2165	no	10
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	09605-0017--07-JAN-09-- Peart2007PharmacolThercardio --Reference-IDS.pdf	2421246 af2beb6b8979c3a152aaa7adce956be5002 c515c	no	16
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	09605-0017--07-JAN-09-- Wilson2008BritishJPharmacolA deReview--Reference-IDS.pdf	395356 2d534913b0d8718f29b2fa4f68bd4ea997df 08c4	no	12
<b>Warnings:</b>					
<b>Information:</b>					
11	Foreign Reference	09605-0017--07-JAN-09-- WO2003105666-A2A3-- Reference-IDS.pdf	3550156 2597c48078ab71945e2a0795765a2c3a5d0 ac813	no	95
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	09605-0017--07-JAN-09-- PolosaRAdenosine- receptorsubtypes--Reference- IDS.pdf	1244378 64142a4577etaf96a0e36e3eb16c7f253235 94c6	no	9
<b>Warnings:</b>					
<b>Information:</b>					
13	Fee Worksheet (PTO-06)	fee-info.pdf	32232 ea5715ef7c2102fd9becd479f8e4a8cc2436 9566	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				12513523	

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.